ブライトパス・バイオ㈱
Kawasaki, JP · 2 known investors
BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
Founders & leadership
KN
Kenichi NagaiRepresentative Director & President
Investors · 2
Frequently asked questions
- What does ブライトパス・バイオ㈱ do?
- BrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
- Who are ブライトパス・バイオ㈱'s investors?
- ブライトパス・バイオ㈱'s investors include DBJ Capital, Sumitomo Mitsui Trust nvestment Co. Ltd..
- Where is ブライトパス・バイオ㈱ headquartered?
- ブライトパス・バイオ㈱ is headquartered in Kawasaki, JP.